Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast

Resource impact statement

Resource impact statement: no significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £1 million per year (or £1,800 per 100,000 population).

Point-of-care creatinine devices are already used in some NHS radiology departments. The additional number of NHS providers expected to start using these devices, as a result of this guidance, is small. The incremental cost of testing will be around £9 per test for an estimated additional 37,700 tests per year. Providers currently not using the technology will incur a cost for the intial purchase of the equipment, this cost is included in the above incremental cost per test.

The technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.